Centene Q3 2026 Earnings: Adjusted EPS Rises as Guidance Increases

Centene (NYSE: CNC) reported Q3 2026 total revenue of $50.65 billion, up about 1.9% from $49.69 billion a year earlier, while adjusted diluted EPS increased to $0.58 from $0.50. The quarter ended September 30 produced a GAAP diluted loss of $0.14 per share and a $3.67 billion operating cash outflow, although the health benefits ratio held at 92.7% and the adjusted SG&A ratio improved by 50 basis points.

Core Results

Premium and service revenue increased only 0.5%, but total revenue grew faster because premium tax revenue rose by $750 million to $5.54 billion. Centene reported a $307 million operating loss and a $71 million net loss attributable to the company, while adjusted net earnings increased 18.4% to $290 million.

The large improvement in GAAP results from Q3 2025 requires context because the prior-year quarter included a $6.72 billion goodwill impairment. Adjusted results provide a more comparable view of the underlying year-over-year change.

Adjusted net earnings and adjusted EPS are non-GAAP measures that exclude acquired-intangible amortization, optimization costs and other specified items.

Business and Segment Performance

Medicare was the largest growth contributor, supported by Medicare Prescription Drug Plan membership and premium yield. Medicaid revenue also increased despite lower membership, while Commercial revenue fell 21% as Marketplace enrollment declined.

The company attributed revenue growth to premium yield and PDP membership, Marketplace and Medicaid rate increases, Marketplace risk-adjustment transfers, and state-directed payments. These factors offset lower Marketplace and Medicaid membership.

Total at-risk membership declined approximately 8.1% to 25.7 million. Marketplace membership fell about 41.6% to 3.4 million, and total Medicaid membership declined about 6.4% to 11.9 million. Medicare PDP membership moved in the opposite direction, rising about 12.2% to 8.9 million. Comparisons between Medicaid and Medicare membership are also affected by the CMS transition of certain dual-eligible members to D-SNP-based integration in 2026.

Optimization Costs Create a Wide GAAP–Adjusted Earnings Gap

Centene’s GAAP SG&A expense increased to $3.24 billion from $3.15 billion, lifting the GAAP SG&A ratio to 7.2% from 7.0%. The increase primarily reflected $276 million of severance and contract-exit costs and $35 million of third-party vendor costs related to enterprise optimization.

After excluding specified items, adjusted SG&A expense declined to $2.92 billion from $3.13 billion, and the adjusted expense ratio fell to 6.5%. Centene cited cost management, expense leverage, lower Marketplace membership and growth in the lower-expense PDP business.

The same adjustments explain the difference between the $71 million GAAP net loss and $290 million of adjusted net earnings. The reconciliation included $161 million of acquired-intangible amortization, $307 million of other adjustments and a $107 million tax effect.

Profitability, Cash Flow, and Balance Sheet

The consolidated health benefits ratio remained at 92.7%, but performance differed by product. Commercial and Medicare ratios improved, while Medicaid’s ratio increased slightly.

Commercial benefited from improved Marketplace pricing and risk transfers reflecting membership acuity. Medicare results reflected stronger underlying performance in both Medicare Advantage and PDP. The prior-year consolidated ratio also benefited from a reduction in the Medicare Advantage premium deficiency reserve, while no such reserve adjustment occurred in Q3 2026.

Operating activities used $3.67 billion of cash during the quarter, primarily because of the timing of pass-through, premium and other payments. This quarterly outflow should be distinguished from the nine-month result: operating activities generated $4.29 billion during the first nine months of 2026, compared with $4.65 billion a year earlier.

Centene ended the quarter with $39.85 billion of cash, investments and restricted deposits, including $38.43 billion held in regulated entities. Cash available for general corporate use was $175 million. Medical claims liabilities totaled $21.50 billion, and days in claims payable increased by one day sequentially to 48 days.

Total debt was approximately $15.5 billion at quarter-end, with no borrowings under the $4.0 billion revolving credit facility. Centene repurchased $558 million of senior notes during Q3 and subsequently redeemed the remaining $569 million of its 2027 senior notes in October, reducing debt by $1.1 billion since June 30.

2026 Guidance

Centene raised both its GAAP and adjusted EPS floors, with the adjusted EPS floor increasing by $0.40. It also lowered its HBR and interest-expense ranges, indicating improved expectations for medical-cost performance and financing expense.

Management Commentary

CEO Sarah London attributed the faster-than-anticipated earnings recovery to underlying performance in Centene’s core businesses. Management’s commentary emphasized continued margin improvement, completing 2026 execution priorities and carrying that progress into 2027.

Recent Insider Transactions

The supplied insider data identified two August 2026 sales by General Counsel Christopher A. Koster. It also listed eight zero-price director stock awards among the latest ten reported entries; those grants should not be treated as open-market purchases.

Across the broader six-month summary, insiders purchased 46,141 shares and sold 184,103 shares, resulting in net sales of 137,962 shares. These transactions do not, by themselves, establish insiders’ views of Centene’s prospects.

Risks Investors Should Watch

• Medical-cost pressure remains significant. The consolidated HBR stayed at 92.7%, and Medicaid’s ratio increased by 20 basis points. Future results depend on pricing and government rate adjustments keeping pace with medical trends.
• Membership continues to contract in major businesses. Total at-risk membership declined about 8.1%, led by substantial Marketplace attrition and lower Medicaid enrollment. Revenue growth therefore relies more heavily on pricing, product mix and PDP expansion.
• Quarterly cash flow can be volatile. Q3’s $3.67 billion operating outflow was attributed to payment timing, but continued differences between earnings and cash generation could affect capital flexibility.
• Optimization carries near-term GAAP costs. Severance, contract exits and vendor expenses lowered reported earnings, and the expected benefits depend on successful execution of the company’s restructuring initiatives.

Conclusion

Centene’s Q3 2026 results showed limited premium and service revenue growth but improving adjusted earnings, supported by Medicare performance, Marketplace pricing and lower adjusted administrative expenses. The main offsets were declining Marketplace and Medicaid membership, a quarterly operating cash outflow and substantial optimization costs. Investors’ next checkpoints are whether the improved HBR outlook holds, adjusted cost reductions continue and membership pressure stabilizes.